Nxera restructures for profitability, focuses on GPCR pipeline

Nxera Pharma is implementing a focused restructuring to achieve its 2030 vision of net sales of at least JPY50 billion and an operating profit margin of at least 30%. The plan emphasizes R&D on best-in-class GPCR targets using its NxWave™ platform, with a strategic focus on next-generation therapies for obesity, metabolic, and endocrine disorders. The company will reduce FY2026 cash R&D expenditure by approximately JPY3.5bn at its UK pharmaceutical operations and streamline its executive team from ten to seven by March 2026.

Workforce reductions of about 15% across Japan and UK operations are planned, with no impact in Switzerland and South Korea. Nxera will recognize one-time restructuring charges of approximately JPY500m in FY2025. The company expects to deliver near-term cost savings of at least JPY1.0bn year-on-year from FY2026, driven by focused restructuring and renewed R&D efficiency.

Nxera's strong cash and liquid investments of JPY30.9bn provide flexibility for the restructuring. Performance-linked remuneration for executives for FY2025 will be materially reduced. The company's pipeline shows progress, with several partnered programs advancing through clinical development and key milestones expected in FY2026.